MétaCan
Menu
Back to cohort
Record W4311581561 · doi:10.1186/s13024-022-00586-0

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum

2022· article· en· W4311581561 on OpenAlexaff
Johan Gobom, Andréa L. Benedet, Niklas Mattsson, Laia Montoliu‐Gaya, Nina Schultz, Nicholas J. Ashton, Shorena Janelidze, Stijn Servaes, Mathias Sauer, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero‐Rodriguez, Gunnar Brinkmalm, Henrik Zetterberg, Oskar Hansson, Pedro Rosa‐Neto, Kaj Blennow

Bibliographic record

VenueMolecular Neurodegeneration · 2022
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsMcGill University
FundersHORIZON EUROPE Marie Sklodowska-Curie ActionsNational Institute on AgingOlav Thon StiftelsenMarcus och Amalia Wallenbergs minnesfondH2020 European Research CouncilGun och Bertil Stohnes StiftelseSkånes universitetssjukhusAlzheimer's Drug Discovery FoundationAlzheimerfondenAgneta Prytz-Folkes och Gösta Folkes StiftelseGöteborgs UniversitetKnut och Alice Wallenbergs StiftelseParkinsonfondenHjärnfondenFamiljen Erling-Perssons StiftelseAlzheimer's AssociationStiftelsen för Gamla TjänarinnorLunds UniversitetKonung Gustaf V:s och Drottning Victorias FrimurarestiftelseAnna-Lisa och Bror Björnssons StiftelseSvenska Forskningsrådet FormasEU Joint Programme – Neurodegenerative Disease ResearchUK Dementia Research InstituteVetenskapsrådetDemensförbundetBrightFocus Foundation
KeywordsEpitopeDementiaCerebrospinal fluidBiomarkerDiseaseAlzheimer's diseaseNeurologyAntibodyMedicineFrontotemporal dementiaPathologyInternal medicineOncologyImmunologyChemistryPsychiatryBiochemistry

Abstract

fetched live from OpenAlex

BACKGROUND: Alzheimer's disease is characterized by an abnormal increase of phosphorylated tau (pTau) species in the CSF. It has been suggested that emergence of different pTau forms may parallel disease progression. Therefore, targeting multiple specific pTau forms may allow for a deeper understanding of disease evolution and underlying pathophysiology. Current immunoassays measure pTau epitopes separately and may capture phosphorylated tau fragments of different length depending on the non-pTau antibody used in the assay sandwich pair, which bias the measurement. METHODS: We developed the first antibody-free mass spectrometric method to simultaneously measure multiple phosphorylated epitopes in CSF tau: pT181, pS199, pS202, pT205, pT217, pT231, and pS396. The method was first evaluated in biochemically defined Alzheimer's disease and control CSF samples (n = 38). All seven pTau epitopes clearly separated Alzheimer's disease from non-AD (p < 0.001, AUC = 0.84-0.98). We proceeded with clinical validation of the method in the TRIAD (n = 165) and BioFINDER-2 cohorts (n = 563), consisting of patients across the full Alzheimer's disease continuum, including also young controls (< 40 years), as well as patients with frontotemporal dementia and other neurodegenerative disorders. RESULTS: Increased levels of all phosphorylated epitopes were found in Alzheimer's disease dementia and Aβ positron emission tomography-positive patients with mild cognitive impairment compared with Aβ-negative controls. For Alzheimer's disease dementia compared with Aβ-negative controls, the best biomarker performance was observed for pT231 (TRIAD: AUC = 98.73%, fold change = 7.64; BioFINDER-2: AUC = 91.89%, fold change = 10.65), pT217 (TRIAD: AUC = 99.71%, fold change = 6.33; BioFINDER-2: AUC = 98.12%, fold change = 8.83) and pT205 (TRIAD: AUC = 99.07%, fold change = 5.34; BioFINDER-2: AUC = 93.51%, fold change = 3.92). These phospho-epitopes also discriminated between Aβ-positive and Aβ-negative cognitively unimpaired individuals: pT217 (TRIAD: AUC = 83.26, fold change = 2.39; BioFINDER-2: AUC = 91.05%, fold change = 3.29), pT231 (TRIAD: AUC = 86.25, fold change = 3.80; BioFINDER-2: AUC = 78.69%, fold change = 3.65) and pT205 (TRIAD: AUC = 71.58, fold change = 1.51; BioFINDER-2: AUC = 71.11%, fold change = 1.70). CONCLUSIONS: While an increase was found for all pTau species examined, the highest fold change in Alzheimer's disease was found for pT231, pT217 and pT205. Simultaneous antibody-free measurement of pTau epitopes by mass spectrometry avoids possible bias caused by differences in antibody affinity for modified or processed forms of tau, provides insights into tau pathophysiology and may facilitate clinical trials on tau-based drug candidates.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.309
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations56
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueMolecular NeurodegenerationSame topicAlzheimer's disease research and treatmentsFrench-language works237,207